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aged 5–14 years and that over 95% of these
cases are found in less developed countries.1
Although there are ample data to support
the claim that ARF has virtually disappeared
from industri lised nations, there are fewer
data from low- and middle-income
nations.1,2
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Objectives:  To determine the incidence and clinical features of acute rheumatic fever 
(ARF) in Fiji, and the clinical features of patients presenting to hospital in Fiji with 
rheumatic heart disease (RHD).
Design and setting:  A prospective surveillance study at the Colonial War Memorial 
Hospital in Suva over a 23-month period from December 2005 to November 2007.
 outcome measures:  Incidence of ARF; clinical features of ARF and RHD.
lts:  The average annualised incidence of definite cases of ARF in children aged 
 years was 15.2 per 100 000 (95% CI, 9.0–22.6). The clinical features of ARF were 
r to those in classic descriptions. Carditis was very common, occurring in 79% of 
. There were 103 admissions for RHD in which detailed information was collected, 
the most common reason for admission being cardiac failure (51%). The median 
t admission with RHD was 26.8 years, and there were 10 deaths of patients with 
RHD (case fatality rate, 9.7%).
Conclusions:  Although apparently declining in incidence since the middle of the 
20th century, ARF remains a significant health problem in Fiji. RHD affects young people, 
leading to premature morbidity and mortality. There is an urgent need for effective 
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control of ARF and RHD in Fiji.ate
ha
opR s of acute rheumatic fever (ARF)ve remained stable in many devel-ing countries, despite a dramatic
decline in the incidence of ARF in industri-
alised countries in the 20th century.1 Glob-
ally, it is estimated that more than 330 000
cases of ARF occur each year in children
The most comprehensive recent descrip-
tions of the clinical manifestations of ARF
come from outbreaks in the United States
and from the Australian Indigenous popula-
tion in the Northern Territory; there are few
descriptions of the clinical profile of ARF in
less developed nations.3,4 Likewise, there are
few descriptions of the clinical presentation
of rheumatic heart disease (RHD) in devel-
oping countries.5 We therefore designed a
study to characterise the clinical epidemi-
ology of patients admitted to hospital with
ARF and RHD in Fiji. This study was part of
a series of studies designed to estimate the
burden of group A streptococcal disease in
Fiji and to prepare for potential clinical trials
of group A streptococcal vaccines.
METHODS
A prospective enhanced surveillance study
was conducted at the Colonial War Memor-
ial Hospital in Fiji’s capital, Suva, over the
23-month period from 5 December 2005 to
5 November 2007. The hospital serves the
Central Division of Fiji, which in 2007 had a
population of 340 843 people, predomi-
nantly comprising the two main ethnic
groups of Indigenous Fijians (213 515) and
Indo-Fijians (102 799).6
Surveillance and case definition
Acute rheumatic fever
We used the 2002–2003 World Health
Organization revision of the Jones Criteria
for the diagnosis of ARF.7,8 Patients were
defined as having recurrent ARF if they had
a bona fide past history of ARF or docu-
mented established RHD. We used 80%
upper limit of normal cut-off values for
both antistreptolysin O (238 IU/mL) and
antideoxyribonuclease B (499 IU/mL) titres
that were established specifically for the
Fijian population in a recent study (for 5–
15-year-olds; unpublished data). We also
considered a separate category of “probable
ARF” for patients who fulfilled the clinical
criteria for ARF but did not have raised
antistreptococcal antibody titres in a single
blood sample as defined by our upper
limit.
Rheumatic heart disease
Any patient admitted with a complication of
RHD as the primary reason for admission
was eligible for enrolment in the study.
Complications of RHD were any one or
more of congestive cardiac failure, infective
endocarditis, atrial fibrillation, stroke or
recurrent ARF. We also included patients in
whom a new murmur was detected when
the reason for admission was for confirma-
tion of the diagnosis of RHD.
Statistical analysis
We used population figures from the 2007
national census6 as the basis for denomina-
tor calculations for ARF incidence. For com-
parisons between sexes and ethnic groups,
we used incidence rate ratios for ARF, and
population-adjusted relative risk for RHD.
Data were analysed using Stata, version 10.0
(StataCorp, College Station, Tex, USA).
Ethics approval
Ethics approval was obtained from the Fiji
National Research Ethics Review Commit-
tee, the Fiji National Heath Research Com-
mittee, and the Human Research Ethics
Committees of the University of Melbourne
and the Queensland Institute of Medical
Research. Written informed consent was
obtained from all adults. Children were
enrolled once written consent from a parent
or guardian was obtained, in addition to
written assent provided by individual chil-
dren if they were aged 10 years or older.
RESULTS
Acute rheumatic fever
There were 37 cases of ARF (33 definite and
four probable) detected during the study
period. The 33 definite cases comprised 20
initial episodes and 13 recurrent episodes
(nine with coexisting established RHD, and
four with a past history of ARF but no
RHD); the recurrence rate of ARF was there-
fore 39%.
The median age at diagnosis of definite
ARF was 10.4 years (interquartile range
[IQR], 8.7–14.3 years). The oldest patient
with an episode of definite ARF was 42 yearsJA • Volume 190 Number 3 • 2 February 2009 133
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was 4.6 years old (initial episode). The
average annualised incidence of definite
ARF in children aged 5–15 years was 15.2
per 100 000 (95% CI, 9.0–22.6); when
probable cases were included, the incidence
was 17.7 per 100 000 (95% CI, 11.8–25.6).
The incidence of ARF was higher in Indigen-
ous Fijians (Box 1). The clinical features of
all patients presenting with definite ARF are
summarised in Box 2.
Rheumatic heart disease
There were 106 patients admitted with RHD
as the primary reason for admission. Three
patients did not give consent, so detailed
demographic and clinical information was
available for 103 patients.
The median age of patients presenting
with RHD was 26.8 years (IQR, 19.3–42.0
years). There were 31 patients (30%) aged
less than 20 years, and the youngest patient
was aged 6 years. Forty patients (38%) with
no past history of RHD were diagnosed with
RHD for the first time (median age, 24.7
years; IQR, 17.3–37.2 years). There were 10
deaths, representing an inhospital fatality
rate of 9.7%. The youngest patient who died
was 7.6 years old (median age at death, 33.1
years; IQR, 20.1–42.7 years). The relative
risk of admission for RHD for females com-
pared with males was 2.5 (95% CI, 1.6–
3.8), and the relative risk for Indigenous
Fijians compared with other races was 1.9
(95% CI, 1.2–2.9).
The clinical features of patients with RHD
are summarised in Box 3. Of note, there
were 24 pregnant women admitted with
RHD. Using obstetric data from the Colonial
War Memorial Hospital in 2006 (Dr James
Fong, Head of Obstetrics and Gynaecology,
Colonial War Memorial Hospital, personal
communication) as a denominator, the prev-
alence of RHD in pregnant women in Fiji
was 1.8 per 1000 (95% CI, 0.9–3.1).
There were 99 patients with echocardio-
graphic information available. In these
patients, the most commonly affected valve
was the mitral valve (90 patients). Mitral
stenosis occurred in 53 patients, with the
youngest of these patients aged 12.9 years.
DISCUSSION
Our findings show that ARF and RHD are
significant problems in Fiji, especially in
Indigenous Fijians and young people. The
incidence of ARF in 5–15-year-olds in our
study is comparable to rates in various
outbreaks described in the US in the
1980s.3,9,10 The clinical features of ARF in
our patient group were also similar to those
described during these outbreaks, particu-
larly the high proportion of patients with
carditis.
Comparison of our data for ARF inci-
dence in children aged 5–15 years (15.2 per
100 000) with figures from previous reports
from Fiji indicates that the incidence of ARF
may be declining.11,12 In a study of ARF
2 Clinical features of patients presenting with definite acute rheumatic fever to 
the Colonial War Memorial Hospital, December 2005 to November 2007
ESR = erythrocyte sedimentation rate. ASO = antistreptolysin O. ADB = antideoxyribonuclease B. *Cases in 
which the diagnosis was not made on the basis of chorea alone. † Figures for peak measurements are median 
(interquartile range). ◆
Cases Episodes
All All non-chorea* Initial Recurrent 
Number of patients 33 29 20 13
2 or more major manifestations 14 13 8 6
1 major manifestation 19 16 12 7
Carditis 26 25 15 11
Pericarditis 3 3 2 1
Cardiac failure 3 3 1 2
Polyarthritis 17 16 11 6
Chorea 5 1 3 2
Erythema marginatum 1 1 0 1
Subcutaneous nodules 0 0 0 0
Fever 22 21 14 8
Monoarthritis 4 4 2 2
Polyarthralgia 7 7 3 4
Raised inflammatory markers 30 28 18 12
Prolonged PR on electrocardiogram 2 2 0 2
Recent sore throat (within 14 days) 14 12 10 4
Positive group A streptococcal throat culture 4 4 2 2
Peak temperature (°C)† 38.4 
(37.6–38.9)
38.5 
(37.8–38.9)
38.2 
(37.6–38.9)
38.5 
(37.6–39.2)
Peak ESR (mm/h)† 85 
(45–118)
100 
(63–120)
88 
(40–114)
85 
(60–120)
Peak ASO titre (IU/mL)† 392 
(314–542)
399 
(314–575)
363 
(288–487)
456 
(368–575)
Peak ADB titre (IU/mL)† 400 
(300–800)
400 
(300–800)
600 
(300–800)
400 
(350–800)
1 Demographic features of patients presenting with definite acute rheumatic 
fever to the Colonial War Memorial Hospital, December 2005 to November 
2007
All ages 5–15 years of age
No. of 
cases
Incidence per
100 000 (95% CI)
Incidence rate
ratio (95% CI)
No. of 
cases
Incidence per
100 000 (95% CI)
Incidence rate
ratio (95% CI)
Sex
Female 16 5.0 (2.9–8.2) 1.0 (0.5–2.1) 12 15.5 (8.0–27.0) 1.0 (0.4–2.5)
Male 17 5.1 (3.0–8.2) 12 14.9 (7.7–26.0)
Ethnicity
Indigenous 
Fijian
26 6.4 (4.2–9.4) 2.2 (0.9–6.1) 17 16.4 (9.6–26.3) 1.3 (0.5–3.7)
Other races 7 2.5 (0.9–5.4) 7 12.8 (5.1–26.3)134 MJA • Volume 190 Number 3 • 2 February 2009
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Division of Fiji in 1965–1966, there were
193 admissions for ARF, equating to an
annual incidence in children aged 5–14
years of 144 per 100 000.12 The reasons for
this change in epidemiology are not clear.
However, our data might underestimate the
true incidence of ARF in Fiji because our
study focused on inpatient admissions and
therefore did not detect outpatient presenta-
tions,13,14 or because cases of ARF are not
being recognised by health care work-
ers,15,16 or because some cases of ARF are
very mild and these patients do not present
for medical care.4
The prospective systematic approach to the
burden of RHD in hospital that we used in
this study has not been carried out elsewhere,
that we are aware of. However, it is also likely
that our data have underestimated the true
burden of RHD because hospital admission
data only detect patients with severe sympto-
matic disease, missing outpatients and
younger patients with latent RHD. Despite
this, our data clearly show that RHD causes a
considerable burden of disease in Fiji,
accounting for 13 of 14 cases of infective
endocarditis and nine of 234 strokes (3.8%)
during the study period, and causing signifi-
cant morbidity in pregnant women.
Previous studies have found an inflated
risk of ARF and RHD in Pacific Islanders,
consistent with our findings. For example,
the Maori population in New Zealand has a
rate of ARF at least five times that of white
New Zealanders; in Hawaii, Samoan chil-
dren have a risk of ARF 88 times that of
white children; and in the US, Asians and
Pacific Islanders account for 6.3% of admis-
sions for ARF, even though they account for
only 2.0% of total admissions for any cause
(P < 0.05).9,17,18 The reasons for this
increased risk are not clear.
The young age of patients with estab-
lished RHD, the high proportion of stenotic
valvular lesions and the high recurrence rate
of ARF found in this study all underline the
need for effective control. Recently revital-
ised control efforts are now focused on
improved delivery of, and compliance with,
secondary prophylaxis, as well as case find-
ing through screening for RHD in school
children.15 Other control methods, includ-
ing a group A streptococcal ARF vaccine,
also need to be considered. We found that
the incidence of ARF in Fiji was sufficiently
high for it to be considered in the future as a
clinical endpoint for group A streptococcal
vaccine trials.
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3 Clinical features of 103 patients 
presenting with rheumatic heart 
disease to the Colonial War 
Memorial Hospital, December 
2005 to November 2007
Clinical presentation No.
Cardiac failure 33 
Cardiac failure secondary to 
valvular disease
28
Cardiac failure secondary to 
atrial fibrillation
5
Rheumatic heart disease in pregnancy 24 
Cardiac failure secondary to 
valvular disease
16
Monitoring of rheumatic heart disease 4
Cardiac failure secondary to 
atrial fibrillation
2
New murmur in pregnancy 2
Recurrence of rheumatic fever 9 
Infective endocarditis 11
Atrial fibrillation 10
Stroke 9
Stroke secondary to valvular 
heart disease
4
Stroke secondary to atrial fibrillation 3
Stroke secondary to infective 
endocarditis
2
New murmur 7MJA • Volume 190 Number 3 • 2 February 2009 135
